Evaluation of the Moderna, Pfizer/Biotech, Astrazeneca/Oxford and Sputnik V Vaccines for Covid-19 | Zendy

Joseph Angel De Soto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of the Moderna, Pfizer/Biotech, Astrazeneca/Oxford and Sputnik V Vaccines for Covid-19

Author(s) -

Joseph Angel De Soto

Publication year - 2021

Publication title -

advance research journal of medical clinical and science

Language(s) - English

Resource type - Journals

ISSN - 2455-3549

DOI - 10.15520/arjmcs.v7i01.246

Subject(s) - covid-19 , medicine , pandemic , cytokine storm , virology , attenuated vaccine , family medicine , disease , biology , outbreak , infectious disease (medical specialty) , biochemistry , virulence , gene

The SARs-CoV-2 (COVID-19) virus, which was first identified in December 2019, in Wuhan China, is a respiratory virus that induces respiratory distress and a systemic inflammatory reaction in the vasculature mediated by a cytokine storm. Currently, 72 million people have been infected with 1.6 million deaths giving a mortality rate of 2.2% despite the best post-infective medical intervention available. Due to the rapid spread of the COVID virus and the worldwide pandemic that has developed, the rush for the development of a vaccine has become a priority amongst health care official’s world-wide. In this review, we discuss what is currently known about the mechanism of action, efficacy, and toxicity of three of the most promising vaccines mRNA-1273 (Moderna), BNT162b2 (Pfizer/BioNtech), ChAdOx1 nCoV-19 (Astrazenac/Oxford), and rAd26)/rAd5 (Sputnik V) against COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research